11 research outputs found
Anti-glycopeptide mAb LpMab-21 against Podoplanin
Human podoplanin (hPDPN), which binds to Cātype lectinālike receptorā2 (CLECā2), is involved in platelet aggregation and cancer metastasis. The expression of hPDPN in cancer cells or cancerāassociated fibroblasts indicates poor prognosis. Human lymphatic endothelial cells, lungātype I alveolar cells, and renal glomerular epithelial cells express hPDPN. Although numerous monoclonal antibodies (mA bs) against hPDPN are available, they recognize peptide epitopes of hPDPN. Here, we generated a novel antiāhPDPN mA b, LpMabā21. To characterize the hPDPN epitope recognized by the LpMabā21, we established glycanādeficient CHOāS and HEKā293T cell lines, using the CRISPR/Cas9 or TALEN. Flow cytometric analysis revealed that the minimum hPDPN epitope, in which sialic acid is linked to Thr76, recognized by LpMabā21 is Thr76āArg79. LpMabā21 detected hPDPN expression in glioblastoma, oral squamous carcinoma, and seminoma cells as well as in normal lymphatic endothelial cells. However, LpMabā21 did not react with renal glomerular epithelial cells or lung type I alveolar cells, indicating that sialylation of hPDPN Thr76 is cellātypeāspecific. LpMabā21 combined with other antiāhPDPN antibodies that recognize different epitopes may therefore be useful for determining the physiological function of sialylated hPDPN
Recommended from our members
LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin
Podoplanin (PDPN), also known as Aggrus, possesses three tandem repeat of platelet aggregation-stimulating (PLAG) domains in its N-terminus. Among the PLAG domains, sialylated O-glycan on Thr52 of PLAG3 is essential for the binding to C-type lectin-like receptor-2 (CLEC-2) and the platelet-aggregating activity of human PDPN (hPDPN). Although various anti-hPDPN monoclonal antibodies (mAbs) have been generated, no specific mAb has been reported to target the epitope containing glycosylated Thr52. We recently established CasMab technology to develop mAbs against glycosylated membrane proteins. Herein, we report the development of a novel anti-glycopeptide mAb (GpMab), LpMab-12. LpMab-12 detected endogenous hPDPN by flow cytometry. Immunohistochemical analyses also showed that hPDPN-expressing lymphatic endothelial and cancer cells were clearly labeled by LpMab-12. The minimal epitope of LpMab-12 was identified as Asp49āPro53 of hPDPN. Furthermore, LpMab-12 reacted with the synthetic glycopeptide of hPDPN, corresponding to 38ā54 amino acids (hpp3854: 38-EGGVAMPGAEDDVVTPG-54), which carries Ī±2ā6 sialylated N-acetyl-D-galactosamine (GalNAc) on Thr52. LpMab-12 did not recognize non-sialylated GalNAc-attached glycopeptide, indicating that sialylated GalNAc on Thr52 is necessary for the binding of LpMab-12 to hPDPN. Thus, LpMab-12 could serve as a new diagnostic tool for determining whether hPDPN possesses the sialylation on Thr52, a site-specific post-translational modification critical for the hPDPN association with CLEC-2
Recommended from our members
LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin
Podoplanin (PDPN), also known as Aggrus, possesses three tandem repeat of platelet aggregation-stimulating (PLAG) domains in its N-terminus. Among the PLAG domains, sialylated O-glycan on Thr52 of PLAG3 is essential for the binding to C-type lectin-like receptor-2 (CLEC-2) and the platelet-aggregating activity of human PDPN (hPDPN). Although various anti-hPDPN monoclonal antibodies (mAbs) have been generated, no specific mAb has been reported to target the epitope containing glycosylated Thr52. We recently established CasMab technology to develop mAbs against glycosylated membrane proteins. Herein, we report the development of a novel anti-glycopeptide mAb (GpMab), LpMab-12. LpMab-12 detected endogenous hPDPN by flow cytometry. Immunohistochemical analyses also showed that hPDPN-expressing lymphatic endothelial and cancer cells were clearly labeled by LpMab-12. The minimal epitope of LpMab-12 was identified as Asp49āPro53 of hPDPN. Furthermore, LpMab-12 reacted with the synthetic glycopeptide of hPDPN, corresponding to 38ā54 amino acids (hpp3854: 38-EGGVAMPGAEDDVVTPG-54), which carries Ī±2ā6 sialylated N-acetyl-D-galactosamine (GalNAc) on Thr52. LpMab-12 did not recognize non-sialylated GalNAc-attached glycopeptide, indicating that sialylated GalNAc on Thr52 is necessary for the binding of LpMab-12 to hPDPN. Thus, LpMab-12 could serve as a new diagnostic tool for determining whether hPDPN possesses the sialylation on Thr52, a site-specific post-translational modification critical for the hPDPN association with CLEC-2
Binding assay of LpMab-12 against sialylated glycopeptide of hPDPN using ELISA.
<p>Strategy for the sialylated glycopeptide synthesis. SA, sialic acid; Gal, galacose; GalNAc, <i>N</i>-acetyl-<sub>D</sub>-galactosamine.</p
Immunohistochemical analysis of the oral cancer and heart tissue samples using LpMab-12 and LpMab-7.
<p>Serial sections of the tissues with oral cancer were incubated with LpMab-12 (A-D) or LpMab-7 (E-H), followed by the development with the EnVision+ kit and counterstaining with hematoxylin, or the HE staining (I-L). Arrows, lymphatic endothelial cells; arrowheads, vascular endothelial cells. Scale bars: 100 Ī¼m. LpMab-12 stains lymphatic vessels with high efficiency, similarly to LpMab-7.</p
The reaction of LpMab-12 against glycopeptides of hPDPN.
<p>The reaction of LpMab-12 against glycopeptides of hPDPN.</p
Epitope mapping of LpMab-12 by Western blot analysis and flow cytometry.
<p>(A) CHO-K1 cells were transfected with a plasmid expressing wild-type hPDPN with the FLAG-tag added to the C-terminus (WT), or the FLAG-tag hPDPN containing a point mutation in the sequence E47A-E57A, as indicated in the figure. Total cell lysates from the transfected cell lines were analyzed by Western blot with LpMab-12 or LpMab-7, as a positive control for hPDPN expression. Immunoblot with anti-FLAG antibody was also used as well to establish the expression of exogenous hPDPN. Anti-IDH1 and anti-Ī²-actin mAbs were used as internal controls to show that total proteins are equal protein load. Red arrow, 40-kDa; blue arrow, 30-kDa. (B) CHO-K1 cells transfected as in (A) were analyzed by flow cytometry using indirect immunolabeling with LpMab-12. Cells exposed to the secondary anti-mouse IgG only were used as a negative control (Control).</p
Schematic summary of the epitopes for several anti-hPDPN mAbs.
<p>Glycosylation sites are shown (<i>O</i>-glycan). Numbers indicate amino acid position. GpMab, anti-glycopeptide mAb; PLAG, platelet aggregation-stimulating.</p